American Journal of Clinical Dermatology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Treatments for Non-Syndromic Inherited Ichthyosis, Including Emergent Pathogenesis-Related Therapy
AbstractThe term ‘inherited ichthyosis’ refers to a heterogeneous group of mendelian disorders of cornification that involve the integument with varying degrees of scaling. The management of ichthyosis poses a challenge for most physicians. Treatment options proposed in the literature include moisturizers, topic al keratolytics, topical and systemic vitamin D analogues, and topical and systemic retinoids; however, some of these modalities are less reliable than others. Despite the therapeutic impasse imposed by the options above, the emergence of pathogenesis-based treatments along with novel gene therapies appear prom...
Source: American Journal of Clinical Dermatology - August 12, 2022 Category: Dermatology Source Type: research

Deucravacitinib for the Treatment of Psoriatic Disease
This article aims to review the current knowledge on deucravacitinib, a new oral drug that selectively inhibits TYK2, granting it a low risk of off-target effects. After good efficacy and safety results in a phase II, placebo-controlled trial, two phase III, 52-week trials evaluated deucravacitinib 6  mg against placebo and apremilast—an active comparator. POETYK PSO-1 and PSO-2 involved 1688 patients with moderate-to-severe psoriasis. After 16 weeks, in both studies, over 50% of patients treated with deucravacitinib reached PASI75, which was significantly superior to placebo and apremilast. In POETYK PSO-1, these resu...
Source: American Journal of Clinical Dermatology - August 12, 2022 Category: Dermatology Source Type: research

Treatments for Non-Syndromic Inherited Ichthyosis, Including Emergent Pathogenesis-Related Therapy
AbstractThe term ‘inherited ichthyosis’ refers to a heterogeneous group of mendelian disorders of cornification that involve the integument with varying degrees of scaling. The management of ichthyosis poses a challenge for most physicians. Treatment options proposed in the literature include moisturizers, topic al keratolytics, topical and systemic vitamin D analogues, and topical and systemic retinoids; however, some of these modalities are less reliable than others. Despite the therapeutic impasse imposed by the options above, the emergence of pathogenesis-based treatments along with novel gene therapies appear prom...
Source: American Journal of Clinical Dermatology - August 12, 2022 Category: Dermatology Source Type: research

Psychological Therapies and Mind –Body Techniques in the Management of Dermatologic Diseases: A Systematic Review
ConclusionsBased on the analysis of included studies and an assessment of their quality of evidence, the most promising interventions are cognitive behavioral therapy, mindfulness-based interventions, and habit reversal therapy. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - August 9, 2022 Category: Dermatology Source Type: research

Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
ConclusionsPharmacokinetic equivalence was demonstrated, with highly similar efficacy and immunogenicity, and comparable safety observed in patients with chronic plaque psoriasis who received either adalimumab RP continuously or who switched between adalimumab RP and BI  695501.Trial RegistrationClinicalTrials.gov: NCT03210259 (registered July 2017); Eudract.ema.europa.eu: 2016-002254-20. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - August 7, 2022 Category: Dermatology Source Type: research

Real-World Considerations of Candidacy for Biologics in Hidradenitis Suppurativa
AbstractHidradenitis suppurativa (HS) is a chronic, progressive inflammatory skin disease that is often recalcitrant to multiple treatments. In determining biologic candidacy for patients with HS, we propose a paradigm shift away from Hurley staging and towards consideration of other variables. Biologics represent a long-term treatment option for HS that may serve as a disease-modifying agent. These medications are typically initiated in patients with moderate to severe disease, which, based on inclusion criteria in clinical trials, is often defined as Hurley stage II or III disease, at which point irreversible tissue dama...
Source: American Journal of Clinical Dermatology - August 5, 2022 Category: Dermatology Source Type: research

Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database
ConclusionPatients should be counseled about these potential dermatologic reactions to the COVID-19 vaccines. Most occur within the first few days after vaccination, and are mild and self-limiting. Patients should therefore be encouraged that it is safe to receive the COVID-19 vaccine from a dermatological perspective. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - August 5, 2022 Category: Dermatology Source Type: research

Real-World Considerations of Candidacy for Biologics in Hidradenitis Suppurativa
AbstractHidradenitis suppurativa (HS) is a chronic, progressive inflammatory skin disease that is often recalcitrant to multiple treatments. In determining biologic candidacy for patients with HS, we propose a paradigm shift away from Hurley staging and towards consideration of other variables. Biologics represent a long-term treatment option for HS that may serve as a disease-modifying agent. These medications are typically initiated in patients with moderate to severe disease, which, based on inclusion criteria in clinical trials, is often defined as Hurley stage II or III disease, at which point irreversible tissue dama...
Source: American Journal of Clinical Dermatology - August 5, 2022 Category: Dermatology Source Type: research

Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database
ConclusionPatients should be counseled about these potential dermatologic reactions to the COVID-19 vaccines. Most occur within the first few days after vaccination, and are mild and self-limiting. Patients should therefore be encouraged that it is safe to receive the COVID-19 vaccine from a dermatological perspective. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - August 5, 2022 Category: Dermatology Source Type: research

Correction  to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - August 4, 2022 Category: Dermatology Source Type: research